Navigation Links
Delcath Systems Receives Refusal to File Letter From FDA
Date:2/22/2011

NEW YORK, Feb. 22, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration (FDA) for the New Drug Application (NDA) for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.  Delcath expects to submit a formal meeting request to the FDA this week and intends to meet with the FDA at the earliest opportunity to discuss the issues raised and to confirm our understanding of the remedies required for the filing to be accepted.  Based on management's current understanding of the information in the FDA's letter, the Company intends to resubmit the NDA by September 30, 2011.  

In accordance with application regulations, the FDA has the ability to formally file or refuse to file an application within 60 days of the completion of the submission, which occurred on December 22, 2010.  Neither the acceptance nor non-acceptance of the NDA filing is a determination of the approvability of the chemosaturation system.

"The FDA's letter requested information involving manufacturing plant inspection timing, product and sterilization validations and additional safety information that we already planned on filing with our 120 day safety update in April, as well as additional statistical analysis clarification," said Eamonn P. Hobbs, CEO & President of Delcath Systems. "We believe that we will be able to provide the requested information in an updated application and we expect to resubmit the NDA by the end of the third quarter of this year.  In the meantime, the CE Mark Technical File review process for marketing approval of the Hepatic ChemoSAT™ Delivery System continues on schedule.  Our expec
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Achieves ISO 13485 Certification
2. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
3. Delcath Systems Announces Third Quarter Progress Report Conference Call
4. Delcath Strengthens Research and Development Team with Key Appointments
5. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
6. Delcath to Present at the William Blair Emerging Growth Stock Conference
7. Delcath to Present at the JMP Securities Healthcare Conference
8. Delcath Systems Announces Completion of Common Stock Offering
9. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
10. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
11. Delcath Systems Announces Second Quarter Progress Report Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Congressional Leaders to Introduce Legislation , WASHINGTON , ... Congressional Network (ACPCN) will join congressional leaders tomorrow to ... Savings Act." The bill by U.S. Rep. G.K. ... management (PBM) companies for medications. , "Congress is prepared ...
... AMD LASERS, the world leader in comprehensive and affordable ... Waclawik as Chief Operating Officer. In this newly created ... operations, procurement, production, quality assurance, and general financial oversight ... effort on the next-generation of product development in order ...
Cached Medicine Technology:Pharmacists Work with Congress to Address PBM Abuses 2AMD LASERS Announces the Addition of Bart Waclawik, New Chief Operating Officer 2
(Date:4/23/2014)... internal surface area of the gastro-intestinal tract has long ... meters. Scientists at the Sahlgrenska Academy have used refined ... "Actually, the inner surface of the gastro-intestinal tract is ... scientist Lars Fndriks. , The digestive tract, which passes ... the intestines, has a length of about 5 meters ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Parents and physicians concerned about an increase in ... can breathe a sigh of relief. According to a ... years worth of data from states with and without ... to increased use among adolescents. The study is published ... of Adolescent Health . , "Any time a ...
(Date:4/23/2014)... the bottom of Alzheimer,s disease has been a ... controversies. In the latest crook in the research ... the interaction between proteins associated with the disease. ... ACS Chemical Neuroscience , could have important implications ... Krzysztof Nieznanski and colleagues explain that for years, ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
Breaking Medicine News(10 mins):Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2
... HealthDay Reporter , TUESDAY, Feb. 1 (HealthDay News) ... from meningococcal meningitis, a potentially deadly infection of the ... up-to-date whooping cough vaccines in light of recent outbreaks, ... American Academy of Pediatrics issues updated vaccination guidelines annually. ...
... Society for Therapeutic Radiology and Oncology (ESTRO), the European ... for Medical Oncology (ESMO) in collaboration with other European ... on the 3rd International Conference on innovative approaches In ... on multidisciplinarity and innovation, this meeting will specifically cover ...
... Hospitals Case Medical Center and Case Western Reserve University ... addressing the lack of knowledge about causes and risk ... five-year study is funded by the National Cancer Institute ... Ovarian cancer, though relatively rare, is the most lethal ...
... for breast cancer delivers consistent rates of cancer detection and ... published online and in the April print edition of ... mammography at identifying suspicious areas of the breast, it is ... which can result in additional testing and false-positive results that ...
... charities and health organizations must tread carefully when ... risk compromise health promotion goals, states an editorial ... Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj110085.pdf . ... for health charities and organizations because they bring ...
... HealthDay Reporter , MONDAY, Jan. 31 (HealthDay News) ... stroke, they appear to have better odds of surviving one ... might seem odd since conventional wisdom says black patients typically ... in general. However, the same trend has been noticed in ...
Cached Medicine News:Health News:Pediatricians Issue New Vaccination Recommendations 2Health News:Pediatricians Issue New Vaccination Recommendations 3Health News:3rd international conference on innovative approaches in head and neck oncology 2Health News:New clinical trial to determine ovarian cancer risks in African-American women 2Health News:Repeat MRI screening for breast cancer results in fewer false positives 2Health News:Survival After Stroke Better for Blacks 2Health News:Survival After Stroke Better for Blacks 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: